Samsung Biologics moved aggressively to expand into peptide therapeutics by launching an all-cash tender offer for Switzerland-based PolyPeptide Group for about $1.8 billion. The deal is Samsung Biologics’ largest acquisition to date and is designed to broaden its modality footprint beyond antibodies and ADCs. PolyPeptide brings development-to-commercial capabilities and peptide API history across multiple geographies, with strategic emphasis on obesity and diabetes assets, including GLP-1-related demand. Samsung framed the purchase as a way to secure proven peptide manufacturing capability and customer relationships while supporting a late-stage peptide project pipeline. The transaction also expands Samsung’s service platform ambitions into an area where many pharma programs increasingly depend on specialized peptide chemistry, manufacturing, and regulatory-facing development. Pending completion, Samsung expects the combination of scale and peptide-specific expertise to accelerate new peptide launches and improve responsiveness to shifting GLP-1 and beyond-GLP-1 demand profiles.